Education
About Us
Working with TipRanks
Follow Us
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
ALA Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.13
Previous CloseN/A
Volume194.12K
Average Volume (3M)1.58M
Market Cap
AU$94.16M
Enterprise ValueAU$73.59M
Total Cash (Recent Filing)AU$19.37M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,207,183,700
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseArovella’s essentially debt-free balance sheet and material equity increase (from ~3.8M to ~20.1M) reduce interest burden and financial distress risk. This durable capital buffer supports multi-period R&D spending and provides flexibility to fund trials or pursue partnerships without immediate refinancing pressure.
Focused Cell Therapy / CAR PlatformA dedicated focus on immunotherapies and CAR cell therapy aligns the company with a structural growth area in oncology. This specialization builds domain expertise, increases attractiveness for partnerships or licensing, and offers long-term upside if clinical assets advance toward commercialization.
Predictable Cash Burn Relative To Accounting LossFree cash flow tracking net loss near ~1x means cash outflows are broadly aligned with reported losses, improving predictability of financing needs. For a development-stage biotech, consistent cash dynamics allow more reliable planning of capital raises and trial scheduling over the medium term.
Bears Say
Persistent Large Operating LossesSustained negative EBIT and net losses erode equity and force recurrent fundraising. Over time this can dilute shareholders, divert management attention to financing, and create pressure to cut or slow development programs if capital access tightens, posing long-term viability risks absent clinical success.
Volatile, Minimal Revenue BaseRevenue is small and highly volatile, including a sharp 2025 decline, so operations cannot meaningfully self-fund. This structural lack of recurring revenue heightens dependency on external capital and increases execution risk for multi-period clinical plans and sustaining R&D spend.
Precommercial, Clinical-stage Program RiskBeing precommercial with programs in preclinical/clinical stages creates long development timelines and binary clinical/regulatory outcomes. Success is uncertain and costly, requiring ongoing funding and partnerships; failure or delays can materially impair future cash flows and valuation over the medium term.
Arovella Therapeutics Limited News
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.13 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$94.16M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,207,183,700 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.82%
12-Months-Change
Fundamentals
Return on Equity
-47.98%
Trailing 12-Months
Asset Growth
62.60%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Technical Analysis
Amplia Therapeutics
―
Alterity Therapeutics
―
Proteomics International Laboratories Ltd.
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---